AstraZeneca's CEO stated the company will uphold its 2025 sales forecast despite potential U.S. tariffs on EU-made pharma products, as long as they align with other industries' rates. Shares dropped over 4% after first-quarter results fell below analyst predictions.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing